What AMP® Heart Failure Partners and Supporters Are Saying

“Moving data science and healthcare forward is at the heart of everything we do at the American Heart Association. The American Heart Association is excited to support the AMP HF program as it brings technology and research together to work toward improved care for heart failure patients.”

“The American Society of Echocardiography (ASE) is proud to contribute and participate in the Accelerating Medicines Partnership^® in Heart Failure initiative to help expedite the diagnosis and treatment of patients suffering from heart failure with preserved ejection fraction (HFpEF). ASE is committed to advancing cardiovascular ultrasound to improve lives, and we look forward to the impact echocardiography can have in detecting and understanding this wide-reaching form of heart failure.”

“Bayer’s focus has been, and will continue to be, patients and their medical needs including our long-standing commitment delivering innovation in the area of cardiovascular diseases. We are excited to be a partner in the Accelerating Medicines Partnership^® in Heart Failure program as it has the potential to advance disease understanding as the basis for developing precision medicine that improves patients’ lives with heart failure with preserved ejection fraction (HFpEF).”

“Heart failure is a leading cause of death in the United States. Despite existing therapies, many patients with heart failure experience a high symptom burden and declining quality of life. We are pleased to partner with AMP^® Heart Failure to advance heart failure research and advance novel treatment strategies. Through this collaboration and by leveraging novel technology, together we can make a bigger impact.”

“Ionis is proud to participate in the Accelerating Medicines Partnership. At Ionis, we know that sick people depend on us. We have a rich history of working closely with academic and industry partners to advance the understanding of complex diseases and develop precision medicine therapies. We are excited to contribute to this public-private partnership and do the same for heart failure with preserved ejection fraction (HFpEF). HFpEF has emerged as a major public health concern that demands such collaborations to understand disease mechanisms and develop innovative medicines.”

“We are truly honored to be joining this global partnership to contribute to the clinical advances of heart failure detection. Although compelling progress has been made in the treatment of many forms of heart disease, death due to heart failure continues to rise nationally. This program fits perfectly with our mission and vision to provide pioneering diagnostics to help clinicians precisely identify heart failure earlier, so they can provide life-saving treatment for all patients throughout their care continuum. Joining the AMP^® HF Program, Ultromics will redefine the heart failure pathway, and contribute to the goal of improving patient outcomes.”